
|Videos|November 14, 2020
(AAO) Study confirms Phase III results for uveitis treatment
Author(s)OT Staff Reports, David Hutton
Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.
Advertisement
Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
How AI is reshaping ophthalmology in 2025 and beyond
2
8 things to know about aflibercept 8 mg for retinal vascular disease
3
From bench to bedside: Evolving realities of gene therapy for inherited retinal diseases
4
AI in ophthalmology research: Ethical implications for medical students
5










































